CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy.

Saved in:
Bibliographic Details
Title: CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy.
Authors: Younis NK; College of Pharmacy, Alnoor University, Mosul, Iraq. nada.khairi@alnoor.edu.iq., Al-Hussainy AF; College of Pharmacy, Ahl al bayt University, Karbala, Iraq., Jyothi SR; Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India., Nayak PP; Department of Medical Oncology, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, 751003, India., Janney JB; Department of Biomedical, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India., Singh G; Department of Physiotherapy, University Institute of Allied Health Sciences, Chandigarh University, Chandigarh, Punjab, India., Polatova D; Scientific-Practical Medical Center for Pediatric Oncology, Hematology and Immunology, Tashkent, Uzbekistan., Sameer HN; Collage of Pharmacy, National University of Science and Technology, Dhi Qar, 64001, Iraq., Salih RM; Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq., Adil M; Pharmacy College, Al-Farahidi University, Baghdad, Iraq.
Source: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2026 Jul; Vol. 28 (7), pp. 2523-2549. Date of Electronic Publication: 2026 Feb 01.
Publication Type: Journal Article; Review
Journal Info: Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1699-3055
DOI:10.1007/s12094-025-04213-4